• 尊龙凯时(中国)登录入口

    集團群站
    • 天道醫藥中國
    • 天道醫藥英國
    • 天道醫藥波蘭
    • 天道醫藥意大利
    • 天道醫藥西班牙
    • 天道醫藥德國
    • 天道醫藥美國
    • 賽灣生物
    • SPL

    更用心，只為更好地護佑健康

    我們將對患者的關懷體現在藥物生產和運轉的全過程細節把控中
    Inhixa
    通用名：
    依諾肝素鈉注射液
    銷售市場：
    歐盟非波蘭
    規格：
    2,000 IU (20 mg)/0.2 mL 4,000 IU (40 mg)/0.4 mL 6,000 IU (60 mg)/0.6 mL 8,000 IU (80 mg)/0.8 mL 10,000 IU (100 mg)/1.0 mL 12,000 IU (120 mg)/0.8 mL 15,000 IU (150 mg)/1 mL 30,000 IU (300 mg)/3 mL 50,000 IU (500 mg)/5 mL 100,000 IU (1000 mg)/10 mL
    適應症：
    Inhixa is indicated in adults for:

    ·Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.

    ·Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.

    ·Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.

    ·Prevention of thrombus formation in extra corporeal circulation during haemodialysis.

    ·Acute coronary syndrome:

    ·Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.

    ·Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).